BMS-564,929
| Use attributes for filter ! | |
| Molar mass | 305. 716 g/mol |
|---|---|
| ChemSpider ID | 8058647 |
| ChEMBL ID | 229264 |
| PubChem CID | 9882972 |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2956267 |
About BMS-564,929
BMS-564,929 is an investigational selective androgen receptor modulator which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men. These symptoms may include depression, loss of muscle mass and strength, reduction in libido and osteoporosis.
